Allarity Therapeutics, Inc.

Allarity Therapeutics, Inc. is a clinical-stage precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need, primarily leveraging its proprietary Drug Response Predictor (DRP®) platform ¹. The DRP® technology is designed to identify gene expression signatures in cancer cells that predict sensitivity to specific cancer therapeutics, aiming to enable smaller, cheaper, and quicker clinical trials with enhanced probability of success by focusing on more responsive patient populations ¹. The company was founded in Denmark in 2004 by Steen Knudsen, Ph.D., and Thomas H. Jensen, both of whom were academic researchers, and was incorporated in Delaware in 2021 ¹.

The core business model revolves around the DRP® platform, which is a bioinformatic engine based on advanced systems biology that assesses the cancer's transcriptome to create drug-specific companion diagnostics ¹. This involves correlating gene expression profiles from cancer cell lines treated with a therapeutic candidate to identify specific RNA changes linked to drug response or resistance ¹. A "biological relevance filter," derived from analyzing over 3,000 human biopsy samples, is applied to refine these biomarkers ¹. The DRP® companion diagnostic typically comprises between 50 and 400 expressed genes ¹. Validation involves retrospectively assessing DRP® data from prior clinical trials to predict patient clinical benefit, with the goal of establishing a cutoff score for prospective trials ¹. The company also generates revenue from service agreements with external biotech clients for DRP® analysis and gene expression services, which generated $0.3 million in revenue in 2025 ¹.

Allarity is now singularly focused on the development of stenoparib and its parallel companion diagnostic, the stenoparib-DRP® ¹. All other assets, including dovitinib, Irofulven, and LiPlaCis, have been terminated from the portfolio ¹. Stenoparib is a novel, dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) and tankyrases, enzymes crucial for DNA damage repair and the WNT cancer cell survival pathway, respectively ¹. It was in-licensed with exclusive worldwide rights from Eisai Pharmaceuticals ¹. The company's DRP® platform has been retrospectively validated in over 35 clinical trials and has 18 granted DRP® patents covering 70 different cancer drugs, with another 9 DRP® patent applications pending covering 3 cancer drugs ¹. The stenoparib-DRP® patent has been granted in Australia and Europe and is under review in the U.S., potentially extending exclusivity for stenoparib with DRP®-guided patient selection beyond 2040 ¹.

For the fiscal year ended December 31, 2025, Allarity Therapeutics reported total revenue of $0.3 million ¹. The company incurred a net loss of $11.2 million ², an improvement from a net loss of $24.5 million in 2024 ². Research and development expenses increased to $6.6 million ³ in 2025 from $6.1 million ³ in 2024. General and administrative expenses decreased significantly to $6.3 million ⁴ in 2025 from $11.4 million ⁴ in 2024. The company reported $14.7 million in cash as of December 31, 2025 ⁵, and an accumulated deficit of $130.2 million ⁶. Net cash used in operating activities was $14.8 million ⁷ for the year ended December 31, 2025.

Comparing 2025 to 2024, total revenue increased from $0 to $0.3 million ¹. Research and development expenses increased by $0.5 million ³, primarily due to an $1.1 million increase in staff costs, partially offset by a $0.5 million decrease in contractor spending ³. General and administrative expenses decreased by $5.1 million ⁴, mainly due to a $5.7 million decrease in legal and professional fees, which included a $2.5 million SEC settlement charge in 2024 ⁴. Other income decreased by $1.0 million ⁴ year-over-year, primarily due to a $2.7 million change in fair value adjustment of warrant derivative liabilities in 2024, partially offset by a $0.2 million increase in interest income, a $0.5 million decrease in interest expense, and a $1.0 million foreign exchange gain in 2025 ⁴.

During 2025, Allarity initiated a new clinical protocol for stenoparib in June 2025, enrolling patients randomized into two dose levels: 600 mg daily (200 mg morning, 400 mg evening) and 800 mg daily (400 mg morning, 400 mg evening), targeting a total of 40 patients with platinum resistant or platinum ineligible ovarian cancer (PROC) ¹. All patients in this trial will undergo a fresh tumor biopsy to assess the DRP® score for clinical benefit prediction ¹. Additionally, a trial combining stenoparib with Temozolomide in relapsed Small Cell Lung Cancer (SCLC), fully funded by the US Veteran’s Administration, opened for enrollment in January 2026 ¹. The company also reached a final settlement with the SEC in March 2025, paying a one-time civil penalty of $2.5 million in April 2025 ¹. The class action lawsuit filed in September 2024 was dismissed in February 2025 ¹.

Allarity Therapeutics anticipates that its expenses will increase substantially in the foreseeable future as it continues to advance stenoparib through clinical trials, pursue regulatory approval, operate as a public company, and conduct preclinical programs and research activities ¹. The company expects to incur significant operating losses for at least the next several years and may never achieve profitability ¹. The existing cash and cash equivalents are estimated to fund operations at least into the second quarter of 2027 ¹. However, this estimate is based on assumptions that may prove incorrect, potentially leading to an earlier depletion of capital resources ¹.

The primary growth area for Allarity is the development of stenoparib, a novel dual inhibitor of PARP and tankyrases, for advanced, recurrent ovarian cancer and relapsed Small Cell Lung Cancer (SCLC) ¹. The company initiated a new Phase 2 clinical protocol in June 2025 for platinum resistant or platinum ineligible ovarian cancer (PROC) patients, aiming to enroll 40 patients across two dose levels (600 mg daily and 800 mg daily) ¹. This trial is designed to deepen the understanding of stenoparib's clinical benefit and advance the stenoparib-DRP® as a companion diagnostic ¹. In January 2026, a randomized, biomarker-driven trial combining stenoparib with Temozolomide in relapsed SCLC, fully funded by the US Veteran’s Administration, commenced enrollment ¹. The company believes stenoparib is distinguished by its lack of myelotoxicity, dual inhibition of Tankyrases 1 and 2, resistance to P-glycoprotein (PgP) mediated export, and ability to cross the blood-brain barrier, suggesting potential for primary brain cancers and brain metastases ¹. The use of the Stenoparib-DRP® companion diagnostic is expected to increase patient benefit rates, avoid adverse events in non-responders, and provide health economics advantages ¹.

The company's operational outlook includes a continued focus on streamlining resources to accelerate stenoparib development ¹. Research and development expenses are expected to increase as clinical trials progress and regulatory approvals are pursued ¹. General and administrative expenses are also anticipated to rise due to increased headcount and the costs associated with operating as a public company, including compliance, insurance, and investor relations ¹. The company relies on third parties for manufacturing investigational products and for clinical trial management, and plans to develop its supply chain and put framework agreements in place with Contract Manufacturing Organizations (CMOs) ¹.

Regarding capital allocation, Allarity will need to secure additional funding through equity sales, debt financing, or collaborations to support future preclinical, clinical, and commercialization activities ¹. In January 2026, Allarity entered a stock purchase agreement providing up to $6 million in additional equity financing ¹. In February 2026, the board approved a stock repurchase plan of up to $5 million over a 12-month period ¹. In March 2026, Allarity issued $20 million in promissory notes to Streeterville Capital as a debt financing ¹.

Management explicitly flagged several structural headwinds and execution risks. The company may face challenges in raising additional funds or securing favorable terms for agreements, which could force delays, reductions, or termination of development and commercialization programs ¹. The inherent risks in product development make predicting the timing and magnitude of expenses or achieving profitability uncertain ¹. Even if product sales are generated, profitability is not guaranteed, and the company may be compelled to reduce or terminate operations ¹. The company is also subject to risks related to its obligations under the Eisai License Agreement, including potential milestone payments up to $94 million and a one-time sales milestone of $50 million if annual sales reach $1 billion or more, plus royalties between 5% and 15% of annual sales ¹. Failure to meet these payment requirements could result in the loss of rights to stenoparib ¹.

Geographic, regulatory, and macro factors identified as constraints include unstable global market and economic conditions, which may make debt or equity financing more difficult, costly, and dilutive ¹. The company's general business strategy may be adversely affected by economic downturns, and there is a risk that service providers or partners may not survive such conditions ¹. Failure to satisfy Nasdaq Capital Market continued listing requirements could lead to delisting, decreasing trading volume and share price, and making capital raising difficult ¹. International operations expose the company to risks such as conflicting laws, regulatory requirements, tariffs, and foreign currency exchange rate fluctuations ¹. The lengthy and unpredictable regulatory approval processes in the U.S., EU, and other countries, along with potential changes in approval policies, could delay or prevent marketing approval for stenoparib ¹. The requirement to obtain approval for the DRP® companion diagnostic alongside stenoparib also poses a significant hurdle ¹.

Allarity Therapeutics faces material risks including the potential for delisting from the Nasdaq Capital Market if it fails to meet continued listing requirements, which could decrease trading volume and share price, and make capital raising difficult ⁸. The company is heavily dependent on securing substantial additional funding, and failure to raise capital when needed or on favorable terms could force delays, reductions, or termination of the stenoparib drug development program or commercialization efforts ⁹. Unstable global market and economic conditions, including military conflicts and sanctions, may adversely affect the company's business, financial condition, and stock price, making financing more difficult, costly, and dilutive ¹⁰. There is a risk of becoming delinquent in payments to Eisai under the license agreement, which could result in the loss of rights to stenoparib and trigger milestone payments up to $94 million and a one-time sales milestone of $50 million for annual sales of $1 billion or more, plus royalties between 5% and 15% of annual sales ¹¹. Clinical trials are inherently expensive, time-consuming, and uncertain, with no guarantee that stenoparib will prove effective or safe, or receive regulatory approval, and results from earlier studies may not be predictive of future outcomes ¹². The company relies on third parties for manufacturing and clinical trials, and their failure to perform or comply with regulations could substantially harm the business ¹³. Furthermore, the proprietary DRP® companion diagnostics platform may fail to successfully identify likely responder patients or additional therapeutic candidates, limiting its utility and commercial value ¹⁴. Cybersecurity threats, including data breaches and cyber-attacks, pose risks to the security of internal computer systems and those of third-party contractors, potentially disrupting operations, delaying regulatory approval efforts, and incurring liability ¹⁵.

Management's message emphasizes a singular focus on the development of stenoparib and its companion diagnostic, the stenoparib-DRP®, following a strategic streamlining of the organization and its finances in 2024 ¹. This re-focusing involved terminating all other assets to dedicate internal resources to accelerating stenoparib development in ovarian cancer ¹. Key strategic priorities include advancing the DRP®-guided Phase 2 clinical trial of stenoparib for ovarian cancer, which initiated a new clinical protocol in June 2025 to enroll 40 patients across two dose levels (600 mg daily and 800 mg daily) ¹. Another priority is the randomized, biomarker-driven trial combining stenoparib with Temozolomide in relapsed Small Cell Lung Cancer (SCLC), which opened for enrollment in January 2026 and is fully funded by the US Veteran’s Administration ¹. Management also highlighted the importance of defining the DRP® score that best predicts clinical benefit to enable its use as a patient selection tool in subsequent pivotal trials ¹. The company believes its existing cash of $14.7 million ⁵ is sufficient to fund operations at least into the second quarter of 2027 ¹, but acknowledges the need for additional funding through equity sales, debt financing, or collaborations to support future preclinical, clinical, and commercialization activities ¹.